Put together the simple table below based on income over the last 15 months and key announcements relating to Cardiocel. Pretty hard to see any Cardiocel impact there yet, will the next quarterly be any clearer I wonder.
I don't expect any big numbers yet, still early days and penetration is the key as everyone keeps saying. But I wonder if we will be able to extrapolate from the next 4C that they are starting to get some sales traction, however small at this early stage.
Column 1 Column 2 Column 3 Column 4 0 Release date Receipts from Customers 1 Current Quarter Year to Date 2 June 2013 4C 30/07/2013 $2,064,000.00 $7,354,000.00 3 September 2013 4C 31/10/2013 $2,198,000.00 $2,198,000.00 4 First Cardiocel Sales to Europe 20/11/2013 5 December 2013 4C 31/01/2014 $1,950,000.00 $4,148,000.00 6 Cardiocel cleared for sale in US 10/02/2014 7 March 2014 4C 24/04/2014 $1,700,000.00 $5,848,000.00 8 Cardiocel sales update - First sales to the US 7/05/2014 9 Share purchase plan 12/05/2014 10 June 2014 4C 30/07/2014 $1,982,000.00 $7,830,000.00 11 Admedus ships Cardiocel to US from new facility 14/08/2014 12 September 2014 4C 31/10/2014 ????? ?????
- Forums
- ASX - By Stock
- AVR
- EACTS 2014
EACTS 2014, page-62
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 17.900 |
1 | 1 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
18.250 | 100 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online